In vivo pharmacodynamic assessments revealed that this nasal delivery system successfully suppressed c‐Myc expression in intracranial tumors, enhanced tumor cell apoptosis, and significantly extended the median survival of glioblastoma‐bearing animals.[79] (c) Gene editing for CNS disease by introducing the CRISPR‐Cas9 system in liposomes. Here, MYC is linked to glioblastoma.